AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead

Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning regulatory submission supported by its IPF drug’s Phase 3 data. The post AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung…

Read More

Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder

The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication The post Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder appeared first on…

Read More

Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show

Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial. The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology. The post Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO…

Read More

Will the Trump Administration implement a Most Favored Nation policy for US drug prices?

Perhaps so according to Politico: Trump early next week is expected to sign an executive order directing aides to pursue the initiative, called “most favored nation,” for a selection of drugs within the Medicare program. The idea would use the administration’s authorities to force prices down… White House officials initially pressed congressional Republicans to draft…

Read More